US20010036444A1 - Formulation and method for treating neoplasms by inhalation - Google Patents

Formulation and method for treating neoplasms by inhalation Download PDF

Info

Publication number
US20010036444A1
US20010036444A1 US09/875,677 US87567701A US2001036444A1 US 20010036444 A1 US20010036444 A1 US 20010036444A1 US 87567701 A US87567701 A US 87567701A US 2001036444 A1 US2001036444 A1 US 2001036444A1
Authority
US
United States
Prior art keywords
drug
patient
method according
formulation
inhalation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/875,677
Other versions
US6419901B2 (en
Inventor
Michael Placke
Anthony Imondi
Michael Brooker
John Frye
Praful Shah
Douglas Flanagan
Maureen Donovan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zivena Inc
Original Assignee
Ventaira Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US3378996P priority Critical
Priority to US09/000,775 priority patent/US6471943B1/en
Application filed by Ventaira Pharmaceuticals Inc filed Critical Ventaira Pharmaceuticals Inc
Priority to US09/875,677 priority patent/US6419901B2/en
Assigned to BATTELLE PULMONARY THERAPEUTICS, INC. reassignment BATTELLE PULMONARY THERAPEUTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BATTELLE MEMORIAL INSTITUTE
Publication of US20010036444A1 publication Critical patent/US20010036444A1/en
Application granted granted Critical
Publication of US6419901B2 publication Critical patent/US6419901B2/en
Assigned to ZIVENA, INC. reassignment ZIVENA, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BATTELLE PHARMA, INC.
Anticipated expiration legal-status Critical
Application status is Expired - Fee Related legal-status Critical

Links